Market Overview

Dr. Reddy's Launches Generic Version of Lamictalets XR in US


Dr. Reddy's Laboratories (NYSE: RDY) announced today that is has
launched Lamotrigine Extended-Release Tablets (25 mg, 50 mg, 100 mg, 200
mg, 300 mg) a therapeutic equivalent generic version of Lamictal®
XR (lamotrigine) in the US market on June 25, 2013, following the
approval by the United States Food & Drug Administration (USFDA) of Dr.
Reddy's ANDA for Lamotrigine XR tablets.

The Lamictal® XR brand and generic had combined U.S. sales of
approximately $300.5 Million MAT for the most recent twelve months
ending in April 2013 according to IMS Health*.

Dr. Reddy's Lamotrigine XR Tablets 25 mg, 50 mg, 100 mg, 200 mg, and 300
mg are available as unit of use bottles of

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (RDY)

View Comments and Join the Discussion!